Pain in knee osteoarthritis is associated with variation in the neurokinin 1 / substance P receptor ( TACR 1 ) gene The substance P receptor gene and painful knee OA

The substance P receptor gene and painful knee OA Sophie C Warner, David A Walsh, Laura L Laslett, Rose A Maciewicz, Anushka Soni, Deborah J Hart, Weiya Zhang, Kenneth R Muir, Elaine M Dennison, Paul Leaverton, Evadnie Rampersaud, Cyrus Cooper, Tim D Spector, Flavia M Cicuttini, Nigel K Arden, Graeme Jones Michael Doherty, Ana M Valdes 1Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom 2Department of Cardiovascular Sciences, University of Leicester & National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, Leicester, United Kingdom

[1]  A. Valdes,et al.  Functional Morphology and Kinesiology the Genetics of Osteoarthritis: a Review , 2022 .

[2]  M. Hallberg.  Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors , 2015, Medicinal research reviews.

[3]  A. Guermazi,et al.  Structural correlates of pain in joints with osteoarthritis. , 2013, Osteoarthritis and cartilage.

[4]  M. Fava,et al.  Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies , 2013, Journal of psychopharmacology.

[5]  H. Storm,et al.  Nociceptive stimuli responses at different levels of general anaesthesia and genetic variability , 2013, Acta anaesthesiologica Scandinavica.

[6]  S. Galea,et al.  A genome-wide association study of posttraumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus , 2012, Molecular Psychiatry.

[7]  F. Cicuttini,et al.  Radiographic osteoarthritis and pain are independent predictors of knee cartilage loss: a prospective study , 2012, Internal medicine journal.

[8]  T. Spector,et al.  The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis , 2011, Annals of the rheumatic diseases.

[9]  Stuart Maudsley,et al.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders. , 2010, CNS & neurological disorders drug targets.

[10]  P. Muglia,et al.  Genome-wide association study of major recurrent depression in the U.K. population. , 2010, The American journal of psychiatry.

[11]  Gun-Hee Kim,et al.  Basic fibroblast growth factor accelerates matrix degradation via a neuro‐endocrine pathway in human adult articular chondrocytes , 2008, Journal of cellular physiology.

[12]  Ariel B. Lindner,et al.  Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism , 2008, Science.

[13]  J. McDougall,et al.  Age alters the ability of substance P to sensitize joint nociceptors in Guinea pigs , 2007, Journal of Molecular Neuroscience.

[14]  Tim D Spector,et al.  The UK Adult Twin Registry (TwinsUK) , 2006, Twin Research and Human Genetics.

[15]  R. Invernizzi,et al.  Blockade of tachykinin NK1 receptors attenuates stress‐induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex , 2006, Journal of neuroscience research.

[16]  P. Nieto,et al.  Tachykinins and tachykinin receptors: structure and activity relationships. , 2004, Current medicinal chemistry.

[17]  C. Cooper,et al.  Birth weight, weight at 1 y of age, and body composition in older men: findings from the Hertfordshire Cohort Study. , 2004, The American journal of clinical nutrition.

[18]  P. Devillier,et al.  mRNA expression of tachykinins and tachykinin receptors in different human tissues. , 2004, European journal of pharmacology.

[19]  F. Wilder,et al.  History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment. The Clearwater Osteoarthritis Study. , 2002, Osteoarthritis and cartilage.

[20]  A. Janecka,et al.  Substance P: transmitter of nociception (Minireview). , 2000, Endocrine regulations.

[21]  W. Kohrt,et al.  Effect of aging. , 2000, Nutrition reviews.

[22]  C. Lindh,et al.  Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc. , 1997, Scandinavian journal of rheumatology.

[23]  N. Rupniak,et al.  Non-specific inhibition of dopamine receptor agonist-induced behaviour by the tachykinin NK1 receptor antagonist CP-99,994 in guinea-pigs. , 1994, European journal of pharmacology.

[24]  K. Marshall,et al.  Substance P and arthritis: analysis of plasma and synovial fluid levels. , 1990, Arthritis and rheumatism.